Ceramide mediates vascular dysfunction in diet-induced obesity by PP2A-mediated dephosphorylation of the eNOS-Akt complex

Diabetes

Volumn 61, Issue 7, 2012, Pages 1848-1859

  Zhang, Quan Jiang ^a,b   Holland, William L ^c   Wilson, Lloyd ^a   Tanner, Jason M ^a   Kearns, Devin ^a   Cahoon, Judd M ^a   Pettey, Dix ^a   Losee, Jason ^a   Duncan, Bradlee ^a   Gale, Derrick ^a   Kowalski, Christopher A ^a   Deeter, Nicholas ^a   Nichols, Alexandrea ^a   Deesing, Michole ^a   Arrant, Colton ^a   Ruan, Ting ^b   Boehme, Christoph ^d   McCamey, Dane R ^d   Rou, Janvida ^d   Ambal, Kapil ^d   Narra, Krishna K ^b   Summers, Scott A ^e,f   Abel, E Dale ^b   Symons, J David ^a,b   more..

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DESATURASE; CERAMIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEAT SHOCK PROTEIN 90; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; THERMOZYMOCIDIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; ENDOTHELIUM CELL; HETEROZYGOTE; HYPERTENSION; IN VITRO STUDY; LIPID DIET; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; VASCULAR DISEASE; VASODILATATION;

ANIMALS; CATTLE; CERAMIDES; DIET, HIGH-FAT; ENDOTHELIAL CELLS; ENZYME INHIBITORS; FATTY ACIDS, MONOUNSATURATED; HSP90 HEAT-SHOCK PROTEINS; HYPERTENSION; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE III; OBESITY; OXIDOREDUCTASES; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-AKT; SERINE C-PALMITOYLTRANSFERASE; VASODILATION;

EID: 84863205222     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-1399     Document Type: Article

References (50)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007 [article online], 2008. Atlanta, GA, U.S. Department of Health and Human Services. Available from http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf. Accessed August 2011
2. Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003;108:1527-1532 (Pubitemid 37176462)
3. Kim F, Tysseling KA, Rice J, et al. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler Thromb Vasc Biol 2005;25:989-994 (Pubitemid 40627844)
4. Symons JD, McMillin SL, Riehle C, et al. Contribution of insulin and Akt1 signaling to endothelial nitric oxide synthase in the regulation of endothelial function and blood pressure. Circ Res 2009;104:1085-1094
5. Edirisinghe I, McCormick Hallam K, Kappagoda CT. Effect of fatty acids on endothelium-dependent relaxation in the rabbit aorta. Clin Sci (Lond) 2006;111:145-151 (Pubitemid 44220528)
6. Du X, Edelstein D, Obici S, Higham N, Zou MH, Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest 2006;116:1071-1080
7. Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 2000;49:1231-1238 (Pubitemid 30439100)
8. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001;357:593-615 (Pubitemid 32735142)
9. Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol 2002;64:749-774 (Pubitemid 34259248)
10. Sessa WC. eNOS at a glance. J Cell Sci 2004;117:2427-2429 (Pubitemid 38877838)
11. Summers SA. Sphingolipids and insulin resistance: the five Ws. Curr Opin Lipidol 2010;21:128-135
12. Holland WL, Summers SA. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev 2008;29:381-402 (Pubitemid 351831506)
13. Chun L, Junlin Z, Aimin W, Niansheng L, Benmei C, Minxiang L. Inhibition of ceramide synthesis reverses endothelial dysfunction and atherosclerosis in streptozotocin-induced diabetic rats. Diabetes Res Clin Pract 2011;93:77-85
14. Wu Y, Song P, Xu J, Zhang M, Zou MH. Activation of protein phosphatase 2A by palmitate inhibits AMP-activated protein kinase. J Biol Chem 2007;282:9777-9788 (Pubitemid 47104626)
15. Chavez JA, Summers SA. Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms. Biochim Biophys Acta 2010;1801:252-265
16. Zhang DX, Zou AP, Li PL. Ceramide-induced activation of NADPH oxidase and endothelial dysfunction in small coronary arteries. Am J Physiol Heart Circ Physiol 2003;284:H605-H612 (Pubitemid 36142888)
17. Zheng T, Li W, Wang J, Altura BT, Altura BM. Sphingomyelinase and ceramide analogs induce contraction and rises in [Ca(2+)](i) in canine cerebral vascular muscle. Am J Physiol Heart Circ Physiol 2000;278:H1421-H1428 (Pubitemid 30395551)
18. Li H, Junk P, Huwiler A, et al. Dual effect of ceramide on human endothelial cells: induction of oxidative stress and transcriptional upregulation of endothelial nitric oxide synthase. Circulation 2002;106:2250-2256 (Pubitemid 35222221)
19. Holland WL, Brozinick JT, Wang L-P, et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 2007;5:167-179
20. Ussher JR, Koves TR, Cadete VJ, et al. Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes 2010;59:2453-2464
21. Shah C, Yang G, Lee I, Bielawski J, Hannun YA, Samad F. Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. J Biol Chem 2008;283:13538-13548
22. Yang G, Badeanlou L, Bielawski J, Roberts AJ, Hannun YA, Samad F. Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am J Physiol Endocrinol Metab 2009;297:E211-E224
23. Park TS, Panek RL, Mueller SB, et al. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2004;110:3465-3471 (Pubitemid 39602225)
24. Hojjati MR, Li Z, Zhou H, et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem 2005;280:10284-10289 (Pubitemid 40395884)
25. Zhang QJ, McMillin SL, Tanner JM, Palionyte M, Abel ED, Symons JD. Endothelial nitric oxide synthase phosphorylation in treadmill-running mice: role of vascular signalling kinases. J Physiol 2009;587:3911-3920
26. Symons JD, Hu P, Yang Y, et al. Knockout of insulin receptors in cardiomyocytes attenuates coronary arterial dysfunction induced by pressure overload. Am J Physiol Heart Circ Physiol 2011;300:H374-H381
27. Perry DK, Bielawska A, Hannun YA. Quantitative determination of ceramide using diglyceride kinase. Methods Enzymol 2000;312:22-31
28. Sullards MC, Merrill AH Jr. Analysis of sphingosine 1-phosphate, ceramides, and other bioactive sphingolipids by high-performance liquid chromatographytandem mass spectrometry. Sci STKE 2001;2001:pl1
29. Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 1988;37:1020-1024 (Pubitemid 19033579)
30. Smith AR, Visioli F, Frei B, Hagen TM. Age-related changes in endothelial nitric oxide synthase phosphorylation and nitric oxide dependent vasodilation: evidence for a novel mechanism involving sphingomyelinase and ceramide-activated phosphatase 2A. Aging Cell 2006;5:391-400 (Pubitemid 44322535)
31. Rodríguez-Crespo I, Moënne-Loccoz P, Loehr TM, Ortiz de Montellano PR. Endothelial nitric oxide synthase: modulations of the distal heme site produced by progressive N-terminal deletions. Biochemistry 1997;36:8530-8538 (Pubitemid 27305136)
32. Chavez JA, Summers SA. Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch Biochem Biophys 2003;419:101-109 (Pubitemid 37329976)
33. Molnar J, Yu S, Mzhavia N, Pau C, Chereshnev I, Dansky HM. Diabetes induces endothelial dysfunction but does not increase neointimal formation in high-fat diet fed C57BL/6J mice. Circ Res 2005;96:1178-1184 (Pubitemid 40827693)
34. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 2002;109:817-826 (Pubitemid 34263158)
35. Fonseca FV, Ravi K, Wiseman D, et al. Mass spectroscopy and molecular modeling predict endothelial nitric oxide synthase dimer collapse by hydrogen peroxide through zinc tetrathiolate metal-binding site disruption. DNA Cell Biol 2010;29:149-160
36. Chavez JA, Knotts TA, Wang L-P, et al. A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J Biol Chem 2003;278:10297-10303 (Pubitemid 36800291)
37. Millward TA, Zolnierowicz S, Hemmings BA. Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci 1999;24:186-191 (Pubitemid 29348452)
38. Imrie H, Abbas A, Kearney M. Insulin resistance, lipotoxicity and endothelial dysfunction. Biochim Biophys Acta 2010;1801:320-326
39. Lüscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. Circulation 2003;108:1655-1661 (Pubitemid 37187795)
40. Williams IL, Wheatcroft SB, Shah AM, Kearney MT. Obesity, atherosclerosis and the vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans. Int J Obes Relat Metab Disord 2002;26:754-764 (Pubitemid 34620866)
41. Li X, Becker KA, Zhang Y. Ceramide in redox signaling and cardiovascular diseases. Cell Physiol Biochem 2010;26:41-48
42. Alewijnse AE, Peters SL. Sphingolipid signalling in the cardiovascular system: good, bad or both? Eur J Pharmacol 2008;585:292-302
43. Park TS, Hu Y, Noh HL, et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 2008;49:2101-2112
44. Michell BJ, Chen Zp, Tiganis T, et al. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem 2001;276:17625-17628
45. Greif DM, Kou R, Michel T. Site-specific dephosphorylation of endothelial nitric oxide synthase by protein phosphatase 2A: evidence for crosstalk between phosphorylation sites. Biochemistry 2002;41:15845-15853 (Pubitemid 36062490)
46. Wei Q, Xia Y. Proteasome inhibition down-regulates endothelial nitric-oxide synthase phosphorylation and function. J Biol Chem 2006;281:21652-21659 (Pubitemid 44181868)
47. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 2002;90:1243-1250 (Pubitemid 34787405)
48. Fontana J, Fulton D, Chen Y, et al. Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ Res 2002;90:866-873 (Pubitemid 34633878)
49. Mukhopadhyay A, Saddoughi SA, Song P, et al. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J 2009;23:751-763
50. Summers SA, Nelson DH. A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing's syndrome. Diabetes 2005;54:591-602 (Pubitemid 40322059)